Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3375880 in Adult Subjects with Moderate-to-Severe Atopic Dermatitis
2018-002401-56Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing LY3375880 with Placebo (2 arms). Started Feb 2019; status: terminated.
02
Drugs
torudokimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-002401-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002401-56.